Aurobindo Pharma receives USFDA approval

New Delhi, Jun 27 (UNI) Aurobindo Pharma Ltd today said it has received US Food and Drug Administration (USFDA) approval to manufacture and market Benazeril Hydrocholoride tablets.

The approval has been received in the strengths of 10,20 and 40 mg, a company statement said.

Benazepril HCI Tablets are the generic equibalent of Novartis Pharmaceuticals Lotensin tablets, which are indicated for the treatment of hypertension.

This is Aurobindo's 69th ANDA approval from the USFDA.

Since April this year, the company has also recieved the final approval for its anti-infective product Panicillin V Potassium tablets.

UNI SR PDT AS1804